CJ Bioscience

At a glance

CJ Bioscience filed 17 disclosures in the last 12 months.

Revenue for 2025 was ₩3.7B, up 6.5% on 2024. It made an operating loss of ₩24.8B. Debt was 35% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.7B and operating loss of ₩11.7B.

The 2025 annual report lists 102 employees with an average tenure of 4.5 years and average pay of ₩79.3M, #460 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩154M each on average. It paid no cash dividend for 2025. 씨제이제일제당㈜ and related parties held 61.95% at year end.

From the 2025 annual report

Staff: 102 (50 men, 52 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩8.1B. Directors and auditors: 5, paid ₩768M in total.

No cash dividend was paid for 2025.

Largest shareholder

씨제이제일제당㈜ holds 61.95%; with 0 related parties the group holds 61.95% of common shares at year end.

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary